Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | Y49BZ | — |
Kinrix was administered to a 6-month-old patient; Kinrix dose was the second dose overall of Dtap and IPV; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 6-month-old male patient who received DTPa-IPV (Kinrix) (batch number Y49BZ, expiry date 17-MAY-2026) for prophylaxis. On 06-FEB-2025, the patient received Kinrix. On 06-FEB-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Kinrix was administered to a 6-month-old patient) and inappropriate schedule of vaccine administered (Verbatim: Kinrix dose was the second dose overall of Dtap and IPV). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-FEB-2025 A nurse called to report Kinrix was administered to a 6-month-old patient. This Kinrix dose was the second dose overall of Dtap and IPV for the patient which led to Inappropriate schedule of vaccine administered. The patient received a dose of Kinrix at an inappropriate age, which led to inappropriate age at vaccine administration.